Solubilization of poorly soluble photosensitizer hypericin by polymeric micelles and polyethylene glycol

General Physiology and Biophysics

Volumn 32, Issue 2, 2013, Pages 201-208

  Búzová, Diana ^a   Kasák, Peter ^b   Miškovský, Pavol ^a,c   Jancura, Daniel ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c INTERNATIONAL LASER CENTER   (Slovakia)

Author keywords

Hypericin; Photodynamic therapy; Polyethylene glycol; Polymeric micelles; Solubilization

Indexed keywords

HYPERICIN; MACROGOL;

CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MICELLE; MOLECULAR WEIGHT; PHOTODYNAMIC THERAPY; SOLUBILIZATION;

EID: 84878526019     PISSN: 02315882     EISSN: 13384325     Source Type: Journal    
DOI: 10.4149/gpb_2013023     Document Type: Conference Paper

References (41)

1. Andresen T. L., Jensen S. S., Jorgensen K. (2005): Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog. Lipid Res. 44, 68-97 http://dx.doi.org/10.1016/j.plipres. 2004.12.001
2. Angelini N., Cubeddu R., Lenci F., Losi A., Pifferi A., Sgarbossa A., Taroni, P., Vecli A., Viappiani C. (1997): Artificial models of biological photoreceptors: effect of quenchers on the fluorescence properties of hypericin embedded in liposomes. J. Photochem. Photobiol. B: Biology 38, 245-252 http://dx.doi.org/10.1016/S1011-1344(96)07475-1
3. Bailon P., Won Ch. Y. (2009): PEG - modified biopharmaceuticals. Expert Opin. Drug Deliv. 6, 1-16 http://dx.doi.org/10.1517/17425240802650568
4. Buriankova L., Buzova D., Chorvat D. Jr., Dureau F., Brault D., Miskovsky P., Jancura D. (2011): Kinetics of hypericin association with low-density lipoproteins. Photochem. Photobiol. 87, 56-62 http://dx.doi.org/10.1111/j.1751- 1097.2010.00847.x
5. Chen B., Xu Y., Roskans T., Delaey E., Agostinis P., Vandenheede J. R., de Witte P. A. M. (2001): Efficacy of antitumoral photodynamic therapy with hypericin: Relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int. J. Cancer 93, 275-282 http://dx.doi.org/10.1002/ ijc.1324
6. Derycke A. S. L., de Witte P. A. M. (2002): Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEGliposomes. Int. J. Oncol. 20, 181-187
7. Falk H., Meyer J. (1994): On the homo- and heteroassociation of hypericin. Monatsh. Chem. 125, 753-762 http://dx.doi.org/10.1007/BF01277637
8. Falk H. (1999): From the photosensitizer hypericin to the photoreceptor stentorin - The chemistry of phenanthroperylene quinones. Angew. Chem. Int. Ed. 38, 3116-3136 http://dx.doi.org/10.1002/(SICI)1521-3773(19991102)38:21< 3116::AID-ANIE3116>3.0.CO;2-S
9. Fishburn C. S. (2008): The Pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97, 4167-4183 http://dx.doi.org/10.1002/jps.21278
10. Galanou M. C., Theodossiou T. A., Tsiourvas D., Sideratou Z., Paleos C. M. (2008): Interactive transport, subcellular relocation and enhanced phototoxicity of hypericin encapsulated in guanidinylated liposomes via molecular recognition. Photochem. Photobiol. 84, 1073-1083
11. Gbur P., Dedic R., Chorvat D. Jr., Miskovsky P., Hala J., Jancura D. (2009): Time-resolved luminescence and singlet oxygen formation after illumination of the hypericin-low density lipoprotein complex. Photochem. Photobiol. 85, 816-823 http://dx.doi.org/10.1111/j.1751-1097.2008.00483.x
12. Hadjur C., Richard M. J., Parat M. A., Jardon P., Favier A. (1996): Photodynamics effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochem. Photobiol. 64, 375-381 http://dx.doi.org/10.1111/ j.1751-1097.1996.tb02474.x
13. Hamblin M. R., Miller J. L., Rizvi I., Loew H. G., Hasan T. (2003): Pegylation of charged polymer-photosensitizer conjugates: effects of photodynamic efficacy. British J. Cancer 89, 937-943 http://dx.doi.org/10.1038/ sj.bjc.6601210
14. Huntosova V., Alvarez L., Bryndzova L., Nadova Z., Jancura D., Buriankova L., Bonneau S., Brault D., Miskovsky P., Sureau F. (2010): Interaction dynamics of hypericin with low-density lipoproteins and U-87 MG cells. Int. J. Pharmaceutics 389, 32-40 http://dx.doi.org/10.1016/j.ijpharm.2010.01.010
15. Huygens A., Kamuhabwa A. R., de Witte P. A. M. (2005): Stability of different formulations and ion pairs of hypericin. Eur. J. Pharm. Biopharm. 59, 461-468 http://dx.doi.org/10.1016/j.ejpb.2004.09.014
16. Immordino M. L., Dosio F., Cattel L. (2006): Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 6, 297-315
17. Kascakova S., Refregiers M., Jancura D., Sureau F., Maurizot J. C., Miskovsky P. (2005): Fluorescence spectroscopic study of hypericin- photosenzitized oxidation of low-density lipoproteins. Photochem. Photobiol. 81, 1395-1403 http://dx.doi.org/10.1562/2005-04-28-RA-503
18. Kiesslich T., Krammer B., Plaetzer K. (2006): Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr. Med. Chem. 13, 2189-2204 http://dx.doi.org/10.2174/092986706777935267
19. Kober M., Pohl K., Efferth T. (2008): Molecular mechanisms underlying St. John's wort drug interactions. Curr. Drug Metab. 9, 1027-1037 http://dx.doi.org/10.2174/138920008786927767
20. Kramer B., Verwanger T. (2012): Molecular response to hypericininduced photodamage. Current Med. Chem. 19, 793-798 http://dx.doi.org/10.2174/ 092986712799034842
21. Kubin, A., Meissner P., Wierrani F., Burner U., Bodenteich A., Pytel A., Schmeller N. (2008): Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-Hypericin. Photochem. Photobiol. 84, 1560-1563 http://dx.doi.org/10.1111/j.1751-1097.2008.00384.x
22. Lavie G., Mazur Y., Lavie D., Meruelo D. (1995): The chemical and biological properties of hypericin: a compound with a broad spectrum of biological activities. Med. Res. Rev. 15, 111-119 http://dx.doi.org/10.1002/med. 2610150203
23. Lukyanov A. N., Torchilin V. P. (2004): Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv. Drug Del. Rev. 56, 1273-1289 http://dx.doi.org/10.1016/j.addr.2003.12.004
24. Millard J. W., Alvarex-Nunez F. A., Yalkowsky S. H. (2002): Solubilization by cosolvents-establishing useful constants for the log-linear model. Int. J. Pharm. 245, 153-166 http://dx.doi.org/10.1016/S0378-5173(02) 00334-4
25. Miskovsky P. (2002): Hypericin - a new antiviral and antitumor photosensitizer: Mechanism of action and interaction with biological macromolecules. Curr. Drug Targets 3, 55-84 http://dx.doi.org/10.2174/ 1389450023348091
26. Mukherjee P., Adhikary R., Halder M., Petrich J. W., Miskovsky P. (2008): Accumulation and interaction of hypericin in lowdensity lipoproteins - a photophysical study. Photochem. Photobiol. 84, 706-712 http://dx.doi.org/10. 1111/j.1751-1097.2007.00234.x
27. Nandi I., Bateson M., Bari M., Joshi H. N. (2003): Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone. AAPS PharmSciTech 4, Article 1
28. Roby A., Erdogan S., Torchilin V. P. (2006): Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killinig in vitro. Eur. J. Pharm. Biopharm. 62, 235-240 http://dx.doi.org/10.1016/j.ejpb.2005.09.010
29. Roslaniec M., Weitman H., Freeman D., Mazur Y., Ehrenberg B. J. (2000): Liposome binding constants and singlet oxygen quantum yields of hypericin, tetrahydroxy helianthrone and their derivatives: studies in organic solutions and in liposomes. Photochem. Photobiol. B Biol. 57, 149-158
30. Saw C. L. L., Olivo M., Chin W. W. L., Soo K. Ch., Heng P. W. S. (2005): Transport of hypericin across chick chorioallantoic membrane and photodynamic therapy vasculature assessment. Biol. Pharm. Bull. 28, 1054-1060 http://dx.doi.org/10.1248/bpb.28.1054
31. Saw C. L. L., Heng P. W. S, Chin W. W. L., Soo K. C., Olivo M. (2006): Enhanced photodynamic activity of hypericin by penetration enhancer N-methyl pyrrolidone formulations in the chick chorioallontoic membrane model. Cancer Letters 238, 104-110 http://dx.doi.org/10.1016/j.canlet.2005.06.026
32. Sezgin Z., Yüksel N., Baykara T. (2006): Preparation and charaterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. J. Pharm. Biopharm. 64, 261-268 http://dx.doi.org/10.1016/j. ejpb.2006.06.003
33. Sezgin Z., Yuksel N., Baykara T. (2007): Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int J. Pharm. 332, 161-167 http://dx.doi.org/10.1016/j.ijpharm. 2006.09.030
34. Torchilin V. P. (2007): Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 24, 1-16 http://dx.doi.org/10.1007/s11095-006-9132-0
35. van de Putte M., Roskams T., Bormans G., Verbruggen A., de Witte P. A. M. (2006): The impact of aggregation on the biodistribution of hypericin. Int. J. Oncol. 28, 655-660
36. van Nostrum C. F. (2004): Polymeric micelles to deliver photosensitizers for photodynamic therapy. Adv. Drug Del. 56, 9-16 http://dx.doi.org/10.1016/j. addr.2003.07.013
37. van Vierken L. E., Vyas T. K., Amiji M. M. (2007): Poly(ethylene glygol)-modified nanocerriers for tumor targeted and intracellular delivery. Phram. Res. 24, 1405-1414 http://dx.doi.org/10.1007/s11095-007-9284-6
38. Veronese F. M., Pasut G. (2005): PEGylation, successful approach to drug delivery. Drug Discov. Today 21, 1451-1458 http://dx.doi.org/10.1016/S1359- 6446(05)03575-0
39. Wattendorf U., Hans P. M. (2008): PEGylation as a tool for the biomedical engineering of surface modified microparticles. J. Pharm. Sci. 97, 4655-4669 http://dx.doi.org/10.1002/jps.21350
40. Zeisser-Labouebe M., Lange N., Gurny R., Delie F. (2006): Hypericin- loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int. J. Pharm. 326, 174-181 http://dx.doi.org/10.1016/j.ijpharm.2006.07.012
41. Zeisser-Labouebe M., Delie F., Gurny R., Lange N. (2009): Benefits of nanoencapsulation for the hypericin-mediated photodetection of ovarian micrometastases. Eur. J. Pharm. Biopharm. 71, 207-213 http://dx.doi.org/10.1016/ j.ejpb.2008.10.005